ARTICLE | Clinical News

Aerpio combo tops Lucentis alone in DME study

July 16, 2015 1:19 AM UTC

Aerpio Therapeutics Inc. (Cincinnati, Ohio) said a combination of its AKB-9778 and Lucentis ranibizumab was superior to Lucentis alone in the Phase IIa TIME-2 study to treat diabetic macular edema (DME). The combination met the primary endpoint of reducing central subfield thickness (CST) vs. Lucentis alone (p=0.008).

Patients receiving the tyrosine kinase receptor 2 ( Tie2) activator as monotherapy in a separate study arm did not have a reduction in CST. ...